This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia


Rasgon, Natalie L., Geist, Cheri L., Kenna, Heather A., Wroolie, Tonita E., Williams, Katherine E., Silverman, Daniel H. S.


PLoS ONE, Volume: 9, No.: 3

Year of Publication



The objective of this study was to examine the effects of estrogen-based hormone therapy (HT) on regional cerebral metabolism in postmenopausal women (mean age = 58, SD = 5) at risk for development of dementia. The prospective clinical trial design included pre- and post-intervention neuroimaging of women randomized to continue (HT+) or discontinue (HT2) therapy following an average of 10 years of use. The primary outcome measure was change in brain metabolism during the subsequent two years, as assessed with fluorodeoxyglucose-18 positron emission tomography (FDG-PET). Longitudinal FDG-PET data were available for 45 study completers. Results showed that women randomized to continue HT experienced relative preservation of frontal and parietal cortical metabolism, compared with women randomized to discontinue HT. Women who discontinued 17-β estradiol (17βE)-based HT, as well as women who continued conjugated equine estrogen (CEE)-based HT, exhibited significant decline in metabolism of the precuneus/posterior cingulate cortical (PCC) area. Significant decline in PCC metabolism was additionally seen in women taking concurrent progestins (with either 17βE or CEE). Together, these findings suggest that among postmenopausal subjects at risk for developing dementia, regional cerebral cortical metabolism is relatively preserved for at least two years in women randomized to continue HT, compared with women randomized to discontinue HT. In addition, continuing unopposed 17bE therapy is associated specifically with preservation of metabolism in PCC, known to undergo the most significant decline in the earliest stages of Alzheimer’s disease. (PsycINFO Database Record (c) 2014 APA, all rights reserved). (journal abstract)

Bibtex Citation

@article{Rasgon_2014, doi = {10.1371/journal.pone.0089095}, url = {}, year = 2014, month = {mar}, publisher = {Public Library of Science ({PLoS})}, volume = {9}, number = {3}, pages = {e89095}, author = {Natalie L. Rasgon and Cheri L. Geist and Heather A. Kenna and Tonita E. Wroolie and Katherine E. Williams and Daniel H. S. Silverman}, editor = {Samuel Kim}, title = {Prospective Randomized Trial to Assess Effects of Continuing Hormone Therapy on Cerebral Function in Postmenopausal Women at Risk for Dementia}, journal = {{PLoS} {ONE}} }


at risk individuals, at risk populations, cerebral cortex, cerebral functions, clinical trials, cortical, dementia, estrogenbased, hormone, hormone therapy, menopause, metabolism, parietal, postmenopausal women, therapy

Countries of Study


Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Risk Factor Modification

Risk Factor Modifications

At risk population